Biocryst Pharmaceuticals Inc SEC filings BCRX
Biocryst Pharmaceuticals Inc has 1,000 filings in SEC EDGAR's recent list, going back to Mar 8, 2016. Its latest annual report, Form ARS, was filed on Apr 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 4, 2026 | Nov 4, 2026 |
| 4 | Insider transaction | Sep 2, 2026 | Aug 31, 2026 |
| 4 | Insider transaction | Sep 2, 2026 | Aug 31, 2026 |
| 4 | Insider transaction | Sep 2, 2026 | Aug 31, 2026 |
| 4 | Insider transaction | Sep 2, 2026 | Aug 31, 2026 |
| 4 | Insider transaction | Sep 2, 2026 | Aug 31, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 14, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Aug 7, 2026 | — |
| S-8 | Employee stock plan registration | Aug 5, 2026 | — |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K/A |
Amended current report
Exit or restructuring costs
|
Aug 4, 2026 | Jun 25, 2026 |
| 8-K |
Current report
Exit or restructuring costs, Regulation FD disclosure
|
Jun 29, 2026 | Jun 25, 2026 |
| 4 | Insider transaction | Jun 15, 2026 | Jun 11, 2026 |
| 4 | Insider transaction | Jun 15, 2026 | Jun 11, 2026 |
| 4 | Insider transaction | Jun 15, 2026 | Jun 11, 2026 |
| 4 | Insider transaction | Jun 15, 2026 | Jun 11, 2026 |
| 4 | Insider transaction | Jun 15, 2026 | Jun 11, 2026 |
| 4 | Insider transaction | Jun 15, 2026 | Jun 11, 2026 |
| 4 | Insider transaction | Jun 15, 2026 | Jun 11, 2026 |
| 4 | Insider transaction | Jun 15, 2026 | Jun 11, 2026 |
| 4 | Insider transaction | Jun 15, 2026 | Jun 11, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 12, 2026 | Jun 11, 2026 |
| 4 | Insider transaction | Jun 2, 2026 | May 29, 2026 |
| 4 | Insider transaction | Jun 2, 2026 | May 29, 2026 |
| 4 | Insider transaction | Jun 2, 2026 | May 29, 2026 |
| 4 | Insider transaction | Jun 2, 2026 | May 29, 2026 |
| 4 | Insider transaction | Jun 2, 2026 | May 29, 2026 |
| 4 | Insider transaction | May 19, 2026 | May 18, 2026 |
| 144 | Notice of proposed sale | May 18, 2026 | — |
| 4 | Insider transaction | May 15, 2026 | May 13, 2026 |
| 144 | Notice of proposed sale | May 13, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | May 12, 2026 | — |
| 10-Q | Quarterly report | May 6, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 6, 2026 | May 6, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
May 4, 2026 | May 4, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | Apr 29, 2026 | — |
| ARS | Annual report to shareholders | Apr 23, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Apr 23, 2026 | — |
| DEF 14A | Proxy statement | Apr 23, 2026 | Jun 11, 2026 |
| 4 | Insider transaction | Apr 7, 2026 | Apr 6, 2026 |
| 3 | Initial insider ownership | Apr 7, 2026 | Apr 6, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Mar 26, 2026 | — |
| 4 | Insider transaction | Mar 24, 2026 | Mar 20, 2026 |
| 144 | Notice of proposed sale | Mar 20, 2026 | — |
| 4 | Insider transaction | Mar 18, 2026 | Mar 16, 2026 |
| 144 | Notice of proposed sale | Mar 16, 2026 | — |
| 4 | Insider transaction | Mar 3, 2026 | Feb 27, 2026 |
| 4 | Insider transaction | Mar 3, 2026 | Feb 27, 2026 |
| 4 | Insider transaction | Mar 3, 2026 | Feb 27, 2026 |
| 4 | Insider transaction | Mar 3, 2026 | Feb 27, 2026 |
| 4 | Insider transaction | Mar 3, 2026 | Feb 27, 2026 |
| 144 | Notice of proposed sale | Mar 2, 2026 | — |
| 10-K | Annual report | Feb 26, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Feb 26, 2026 | Feb 26, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 12, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Feb 9, 2026 | — |
| 4 | Insider transaction | Jan 27, 2026 | Jan 23, 2026 |
| 3 | Initial insider ownership | Jan 27, 2026 | Jan 23, 2026 |
| 8-K/A |
Amended current report
Officer or director change
|
Jan 23, 2026 | Oct 14, 2025 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, New debt, Regulation FD disclosure
|
Jan 23, 2026 | Jan 23, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure, Other events
|
Jan 12, 2026 | Jan 12, 2026 |
| 3 | Initial insider ownership | Jan 9, 2026 | Jan 1, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 9, 2026 | Jan 9, 2026 |
| 4 | Insider transaction | Dec 23, 2025 | Dec 19, 2025 |
| 4 | Insider transaction | Dec 23, 2025 | Dec 19, 2025 |
| 4 | Insider transaction | Dec 23, 2025 | Dec 19, 2025 |
| 144 | Notice of proposed sale | Dec 22, 2025 | — |
| 4 | Insider transaction | Dec 19, 2025 | Dec 18, 2025 |
| 4 | Insider transaction | Dec 19, 2025 | Dec 17, 2025 |
| 4 | Insider transaction | Dec 19, 2025 | Dec 17, 2025 |
| 4 | Insider transaction | Dec 19, 2025 | Dec 17, 2025 |
| EFFECT | Filing | Dec 18, 2025 | — |
| 424B3 | Prospectus | Dec 18, 2025 | — |
| 4 | Insider transaction | Dec 16, 2025 | Dec 12, 2025 |
| 4 | Insider transaction | Dec 16, 2025 | Dec 12, 2025 |
| 4 | Insider transaction | Dec 16, 2025 | Dec 12, 2025 |
| CORRESP | Letter to the SEC | Dec 16, 2025 | — |
| 144 | Notice of proposed sale | Dec 15, 2025 | — |
| S-4/A | Filing | Dec 15, 2025 | — |
| 8-K |
Current report
Other events
|
Dec 12, 2025 | Dec 12, 2025 |
| 8-K |
Current report
Officer or director change
|
Dec 11, 2025 | Dec 9, 2025 |
| 4 | Insider transaction | Dec 3, 2025 | Dec 1, 2025 |
| 144 | Notice of proposed sale | Dec 3, 2025 | — |
| 425 | Filing | Dec 3, 2025 | — |
| 8-K |
Current report
Other events
|
Dec 3, 2025 | Dec 3, 2025 |
| 4 | Insider transaction | Dec 2, 2025 | Nov 28, 2025 |
| 4 | Insider transaction | Dec 2, 2025 | Nov 28, 2025 |
| 4 | Insider transaction | Dec 2, 2025 | Nov 28, 2025 |
| 144 | Notice of proposed sale | Dec 2, 2025 | — |
| 144 | Notice of proposed sale | Dec 1, 2025 | — |
| 144 | Notice of proposed sale | Nov 25, 2025 | — |
| 144 | Notice of proposed sale | Nov 21, 2025 | — |
| S-4 | Registration for a merger or exchange | Nov 20, 2025 | — |
| 4 | Insider transaction | Nov 17, 2025 | Nov 13, 2025 |
| 144 | Notice of proposed sale | Nov 13, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Nov 12, 2025 | — |
| 10-Q | Quarterly report | Nov 4, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 3, 2025 | Nov 3, 2025 |
| 425 | Filing | Oct 14, 2025 | — |
| 425 | Filing | Oct 14, 2025 | — |
| 425 | Filing | Oct 14, 2025 | — |
| 425 | Filing | Oct 14, 2025 | — |
| 8-K |
Current report
Material agreement, Results of operations, Officer or director change, Other events
|
Oct 14, 2025 | Oct 14, 2025 |
| 8-K |
Current report
Material agreement, Other events
|
Oct 1, 2025 | Oct 1, 2025 |
| SCHEDULE 13G | Ownership over 5% (passive) | Sep 19, 2025 | — |
| 4 | Insider transaction | Sep 3, 2025 | Aug 29, 2025 |
| 4 | Insider transaction | Sep 3, 2025 | Aug 29, 2025 |
| 4 | Insider transaction | Sep 3, 2025 | Aug 29, 2025 |
| 4 | Insider transaction | Aug 15, 2025 | Aug 13, 2025 |
| 144 | Notice of proposed sale | Aug 13, 2025 | — |
| S-8 | Employee stock plan registration | Aug 12, 2025 | — |
| 8-K |
Current report
Officer or director change
|
Aug 11, 2025 | Aug 11, 2025 |
| 10-Q | Quarterly report | Aug 5, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 4, 2025 | Aug 4, 2025 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jul 31, 2025 | Jul 25, 2025 |
| 4 | Insider transaction | Jul 28, 2025 | Jul 24, 2025 |
| 3 | Initial insider ownership | Jul 11, 2025 | Jul 7, 2025 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jul 7, 2025 | Jul 7, 2025 |
| 8-K |
Current report
Material agreement
|
Jun 30, 2025 | Jun 27, 2025 |
| 8-K |
Current report
Other events
|
Jun 27, 2025 | Jun 27, 2025 |
| 8-K |
Current report
Other events
|
Jun 25, 2025 | Jun 23, 2025 |
| 4 | Insider transaction | Jun 16, 2025 | Jun 12, 2025 |
| 4 | Insider transaction | Jun 16, 2025 | Jun 12, 2025 |
| 4 | Insider transaction | Jun 16, 2025 | Jun 12, 2025 |
| 4 | Insider transaction | Jun 16, 2025 | Jun 12, 2025 |
| 4 | Insider transaction | Jun 16, 2025 | Jun 12, 2025 |
| 4 | Insider transaction | Jun 16, 2025 | Jun 12, 2025 |
| 4 | Insider transaction | Jun 16, 2025 | Jun 12, 2025 |
| 4 | Insider transaction | Jun 16, 2025 | Jun 12, 2025 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 16, 2025 | Jun 11, 2025 |
| 8-K |
Current report
Officer or director change
|
Jun 4, 2025 | May 31, 2025 |
| 4 | Insider transaction | Jun 3, 2025 | May 30, 2025 |
| 4 | Insider transaction | Jun 3, 2025 | May 30, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 15, 2025 | — |
| 8-K |
Current report
Other events
|
May 14, 2025 | May 14, 2025 |
| 4 | Insider transaction | May 6, 2025 | May 2, 2025 |
| 3 | Initial insider ownership | May 6, 2025 | May 2, 2025 |
| 10-Q | Quarterly report | May 6, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 5, 2025 | May 5, 2025 |
| 8-K |
Current report
Officer or director change
|
May 1, 2025 | Apr 30, 2025 |
| ARS | Annual report to shareholders | Apr 24, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Apr 24, 2025 | — |
| DEF 14A | Proxy statement | Apr 24, 2025 | Jun 12, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Apr 17, 2025 | — |
| 8-K |
Current report
Officer or director change
|
Apr 10, 2025 | Apr 6, 2025 |
| 4 | Insider transaction | Apr 2, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Other events
|
Mar 11, 2025 | Mar 10, 2025 |
| 4 | Insider transaction | Mar 4, 2025 | Feb 28, 2025 |
| 8-K |
Current report
Officer or director change
|
Mar 4, 2025 | Feb 28, 2025 |
| 10-K | Annual report | Feb 25, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure, Other events
|
Feb 24, 2025 | Feb 24, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 13, 2025 | Jan 13, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Jan 10, 2025 | Jan 10, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 8, 2025 | Jan 8, 2025 |
| 4 | Insider transaction | Dec 23, 2024 | Dec 19, 2024 |
| 4 | Insider transaction | Dec 23, 2024 | Dec 19, 2024 |
| 4 | Insider transaction | Dec 23, 2024 | Dec 19, 2024 |
| 4 | Insider transaction | Dec 23, 2024 | Dec 19, 2024 |
| 4 | Insider transaction | Dec 23, 2024 | Dec 19, 2024 |
| 4 | Insider transaction | Dec 17, 2024 | Dec 14, 2024 |
| 4 | Insider transaction | Dec 17, 2024 | Dec 14, 2024 |
| 4 | Insider transaction | Dec 17, 2024 | Dec 14, 2024 |
| 4 | Insider transaction | Dec 17, 2024 | Dec 14, 2024 |
| 4 | Insider transaction | Dec 17, 2024 | Dec 14, 2024 |
| 4 | Insider transaction | Dec 16, 2024 | Dec 13, 2024 |
| 144 | Notice of proposed sale | Dec 13, 2024 | — |
| 4 | Insider transaction | Dec 2, 2024 | Nov 29, 2024 |
| SC 13G/A | Amended ownership over 5% (passive) | Nov 7, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Nov 7, 2024 | — |
| 10-Q | Quarterly report | Nov 5, 2024 | Sep 30, 2024 |
| SC 13G/A | Amended ownership over 5% (passive) | Nov 4, 2024 | — |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 4, 2024 | Nov 4, 2024 |
| SC 13G/A | Amended ownership over 5% (passive) | Oct 17, 2024 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 2, 2024 | Oct 2, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 30, 2024 | Sep 30, 2024 |
| SC 13G/A | Amended ownership over 5% (passive) | Sep 10, 2024 | — |
| 4 | Insider transaction | Sep 3, 2024 | Aug 30, 2024 |
| S-8 | Employee stock plan registration | Aug 6, 2024 | — |
| 10-Q | Quarterly report | Aug 6, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 5, 2024 | Aug 5, 2024 |
| 4 | Insider transaction | Jun 25, 2024 | Jun 24, 2024 |
| 144 | Notice of proposed sale | Jun 24, 2024 | — |
| 4 | Insider transaction | Jun 17, 2024 | Jun 17, 2024 |
| 144 | Notice of proposed sale | Jun 17, 2024 | — |
| 4 | Insider transaction | Jun 14, 2024 | Jun 12, 2024 |
| 4 | Insider transaction | Jun 14, 2024 | Jun 12, 2024 |
| 4 | Insider transaction | Jun 14, 2024 | Jun 12, 2024 |
| 4 | Insider transaction | Jun 14, 2024 | Jun 12, 2024 |
| 4 | Insider transaction | Jun 14, 2024 | Jun 12, 2024 |
| 4 | Insider transaction | Jun 14, 2024 | Jun 12, 2024 |
| 4 | Insider transaction | Jun 14, 2024 | Jun 12, 2024 |
| 4 | Insider transaction | Jun 14, 2024 | Jun 12, 2024 |
| 4 | Insider transaction | Jun 14, 2024 | Jun 12, 2024 |
| 144 | Notice of proposed sale | Jun 14, 2024 | — |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 13, 2024 | Jun 12, 2024 |
| 4 | Insider transaction | Jun 3, 2024 | May 31, 2024 |
| 4 | Insider transaction | Jun 3, 2024 | May 31, 2024 |
| 4 | Insider transaction | May 31, 2024 | May 30, 2024 |
Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- BCRX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Durham, NC
- SEC filer status
- Large accelerated filer
- SEC CIK
- 882796
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.